Immunogen Inc. (IMGN) Elahere Data 'Simply Mirvelous!' - BMO

BMO Capital analyst Etzer Darout reiterated an Outperform rating and $19.00 price target on Immunogen Inc. (NASDAQ: IMGN) following positive phase 3 data on ELAHERE. The analyst called the results "simply mirvelous!'

The analyst commented, "This morning IMGN announced that the Phase 3 MIRASOL trial studying mirvetuximab (Elahere) in patients with FRα-positive platinum-resistant ovarian cancer (PROC) experienced statistically significant improvements in OS, PFS, and ORR becoming the first drug to demonstrate an overall survival benefit in PROC. Management plans to submit MAA in Europe and sBLA in US in 2H 2023. IMGN will host a conference call at 8:00a.m. Maintain OP and target price."

For an analyst ratings summary and ratings history on Immunogen Inc. click here. For more ratings news on Immunogen Inc. click here.

Shares of Immunogen Inc. closed at $5.20 yesterday.

You May Also Be Interested In

• Corteva Inc. (CTVA) PT Raised to $100 at BMO Capital 'Despite Overreaction'
• First Solar (FSLR) PT Lowered to $196 at Jefferies
• Alliant Energy (LNT) PT Lowered to $78 at BMO Capital